Mepolizumab reduces need for corticosteroids among patients with severe asthma

Mepolizumab reduced the need for maintenance oral corticosteroids and systemic corticosteroid bursts among patients with severe asthma, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.
The monoclonal antibody also was well tolerated by patients as it provided disease control, Charles Pilette, MD, professor with the department of pulmonary medicine, Cliniques Universitaires Saint-Luc, Brussels, Belgium, and colleagues wrote in the study.
The REALITI-A prospective, observational cohort study involved 84 centers across Europe and North America and

Mepolizumab reduced the need for maintenance oral corticosteroids and systemic corticosteroid bursts among patients with severe asthma, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.
The monoclonal antibody also was well tolerated by patients as it provided disease control, Charles Pilette, MD, professor with the department of pulmonary medicine, Cliniques Universitaires Saint-Luc, Brussels, Belgium, and colleagues wrote in the study.
The REALITI-A prospective, observational cohort study involved 84 centers across Europe and North America and